News
EVFM
1.060
-0.93%
-0.010
Evofem Biosciences (EVFM) Stock Remains in Spotlight With Contraception Access Deal
Investor Place · 15m ago
Evofem adds 36% on collaboration for birth control method
Following a twofold rise in value yesterday, Evofem Biosciences (NASDAQ:EVFM) is trading ~36% higher in the pre-market Tuesday after the commercial-stage pharma announced an agreement with one of the largest pharmacy benefit
Seekingalpha · 7h ago
BRIEF-Evofem Reaches Agreement With One Of The Largest Pharmacy Benefit Managers In The U.S. For Access To Phexxi
BRIEF-Evofem Reaches Agreement With One Of The Largest Pharmacy Benefit Managers In The U.S. For Access To Phexxi
Reuters · 7h ago
Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has reached an agreement with one of the nation's largest pharmacy benefit managers (PBMs) to ensure most women covered by this plan can fill their Phexxi® (lactic acid, citric acid, potassium bit...
PR Newswire · 7h ago
EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision
Investor Place · 1d ago
Crude Oil Surges 2.5%; Evofem Biosciences Shares Jump
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 50 points on Monday.
Benzinga · 1d ago
Evofem's stock is still up after Friday's Supreme Court decision
Shares of Evofem Biosciences Inc. soared 164.6% in trading on Monday in a rally that began Friday when the Supreme Court decision striking down Roe v. Wade was announced. Evofem makes a birth-control product with a four-year shelf life called Phexxi, a non...
marketwatch.com · 1d ago
EVFM, DTIL and SRRK among mid-day movers
Gainers: Evofem Biosciences (EVFM) +172%. Acutus Medical (AFIB) +97%. NeuroSense (NRSN) +52%. Axsome (AXSM) +42%. Clene (CLNN) +35%. AeroClean (AERC) +28%. Femasys (FEMY) +30%. Scholar Rock Holding (SRRK) +22%. Precision
Seekingalpha · 1d ago
Nasdaq Drops 75 Points; Acutus Medical Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 75 points on Monday.
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 1d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 1d ago
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Benzinga · 1d ago
Evofem's stock jumps 30% after Supreme Court decision on Roe v. Wade
Shares of Evofem Biosciences Inc. soared 30.6% in trading on Friday, hours after the Supreme Court decision striking down Roe v. Wade was announced. Experts have speculated that the court's decision could lead to restrictions on birth control in the future...
marketwatch.com · 4d ago
Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session
Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Benzinga · 4d ago
Evofem's Phexxi birth control method prevented 99% of pregnancies, post analysis shows
Evofem Biosciences (NASDAQ:EVFM) on Thursday said a post analysis of its phase 3 trial evaluating Phexxi showed that the birth control method prevented 99% of pregnancies. The analysis was based
Seekingalpha · 06/16 13:53
BRIEF-Phexxi Prevents 99% Of Pregnancies Per Act Of Intercourse In Post HOC Analysis Of Phase 3 Ampower Clinical Trial Data
reuters.com · 06/16 13:13
Evofem Biosciences Announces Results Of Post Hoc Analysis Of Registrational Phase 3 AMPOWER Trial
  Throughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc Analysis SAN DIEGO, June 16, 2022 /PRNewswire/ -- Evofem Biosciences,
Benzinga · 06/16 12:47
Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial investigating the ability of Phexxi® (lactic acid, citric acid, and potassium bitartrate) to prevent pregnancy.
PR Newswire · 06/16 12:46
BRIEF-Evofem - On June 8, Co Received Notice From Nasdaq That Co Would Be Permitted To Continue Listing On Nasdaq Through Aug 22 To Regain Compliance
reuters.com · 06/14 21:25
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga · 06/06 09:31
More
Webull provides a variety of real-time EVFM stock news. You can receive the latest news about Evofem Bioscienc through multiple platforms. This information may help you make smarter investment decisions.
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd.